LEO Pharma delivers solid first half-year results and strengthens its capital structure
As a result of the solid first half year results, LEO Pharma is now upwards revising its outlook for 2023.
- As a result of the solid first half year results, LEO Pharma is now upwards revising its outlook for 2023.
- Today, LEO Pharma also announced a new capital structure that enables the company to pursue value accretive Business Development and M&A opportunities supporting continued long-term growth.
- The LEO Foundation has taken the opportunity to simplify and further strengthen the capital structure by converting its existing shareholder loans into equity in LEO Pharma.
- Together with our owners and relationship banks, we have now secured a capital structure that supports the future growth both organically and through acquisitions.”
Peter Haahr, CEO of the LEO Foundation said:
“The solid half-year results and strengthened capital structure represent an important milestone in LEO Pharma’s transformation.